MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MaxCyte, Inc.NASDAQ: MXCT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $7.07M fell 20.5% year over year, behind the -14.5% change in trailing-twelve-month gross profit. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.

Context

  • Gross profit amounted to 81.2% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.5% toward the trailing-twelve-month pace of -14.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.07M+24.2% QoQ
Last fiscal yearDec 2025
$26.8M-15.0% YoY
LTMMar 2026
$26.06M-14.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.5%——
1 year-15.0%——
3-year CAGR-11.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
26.8M USD
Year-over-year change
-15.0%
4-year CAGR
-3.0%

Gross Profit vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 gross profit of $26.06M is the 6th highest of the 11 companies compared; the peer median is $19.78M.
  • Its year-over-year change of -14.5% is the 6th highest of 11, against a peer median of -11.4%.
  • Gross profit amounts to 80.7% of revenue for MXCT, versus a peer median of 71.6%.
MXCT Competitors Peer median
Gross Profit for MXCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PREPrenetics Global LimitedLTM Mar 2026$66.34M +249.9%+138.0%58.3%
OWLTOwlet, Inc.LTM Mar 2026$54.45M +23.4%+31.9%50.9%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$38.18M +38.8%+55.6%85.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M -45.8%-31.5%100.0%
LNSRLENSAR, Inc.LTM Mar 2026$26.15M -3.4%+10.8%45.3%
MXCTMaxCyte, Inc.LTM Mar 2026$26.06M -14.5%-11.9%80.7%
PROFProfound Medical Corp.LTM Mar 2026$13.41M +43.6%+56.6%71.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.14M -35.6%—72.2%
AVRAnteris Technologies Global Corp.LTM Mar 2026$523K -60.4%—28.3%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$3.03M -150.0%—489.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025-$12.79M -19.4%—98.2%
Peer median (excluding MXCT) $19.78M-11.4%+43.8%71.6%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.89M44.26M41.29M38.63M33.03M
Cost of Revenue3.65M5.1M4.74M7.1M6.22M
Gross Profit30.25M39.16M36.55M31.53M26.8M
Gross Margin89.2%88.5%88.5%81.6%81.2%
Research & Development15.41M19.51M23.82M22.23M20.82M
Selling, General & Admin31.68M44.48M57.04M56.35M47.04M
Operating Expenses48.44M66.52M84.85M82.72M72.09M
Depreciation & Amortization1.42M2.7M4.17M4.79M5.14M
EBITDA(16.61M)(20.75M)(33.75M)(36.27M)(39.49M)
EBITDA Margin-49.0%-46.9%-81.7%-93.9%-119.6%
Operating Income(18.19M)(27.36M)(48.3M)(51.2M)(45.29M)
Operating Margin-53.7%-61.8%-117.0%-132.5%-137.1%
Interest Income150.8K3.92M10.38M10.14M7.27M
Interest Expense1.04M126.9K000
Other Income / Expenses(893.6K)3.79M10.38M10.14M655K
Income Before Tax(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Pre-Tax Margin-56.3%-53.3%-91.8%-106.3%-135.1%
Income Tax Expense00000
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Net Margin-56.3%-53.3%-91.8%-106.3%-135.1%
EPS (Basic)(0.22)(0.19)(0.37)(0.39)(0.42)
EPS (Diluted)(0.22)(0.19)(0.37)(0.39)(0.42)
Weighted Avg Shares90.62M101.7M103.27M104.85M106.43M
Weighted Avg Shares (Diluted)90.62M101.7M103.27M104.85M106.43M

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.